Jupiter Neurosciences (JUNS) Non Operating Income (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Non Operating Income of $233754.0 for Q4 2025, up 437.45% year-over-year from $43493.3 in Q4 2024, and up 2491.8% quarter-over-quarter from $9019.0 in Q3 2025.
Jupiter Neurosciences (JUNS) Non Operating Income (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Non Operating Income for 3 consecutive years, with $233754.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income rose 437.45% year-over-year to $233754.0; the TTM figure through Dec 2025 stood at $263824.0 (down 58.78% YoY), while the FY2025 annual figure was $263824.0, down 59.51% from the prior year.
- Non Operating Income rose to $233754.0 in Q4 2025 per JUNS's latest filing, from $9019.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $870200.0 in Q2 2024 and bottomed at -$332062.0 in Q3 2023.
- Historically, Non Operating Income has averaged $67780.9 across 3 years, with a median of $9077.5 in 2025.
- Annual changes were most pronounced in 2024 — Non Operating Income tumbled 165.35% — and 2025, when it jumped 437.45%.
- Jupiter Neurosciences' Non Operating Income stood at $105997.0 in 2023, then sank by 165.35% to -$69271.0 in 2024, then surged by 437.45% to $233754.0 in 2025.
- Business Quant data shows JUNS's Non Operating Income at $233754.0 in Q4 2025, $9019.0 in Q3 2025, and $11915.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | 468,548.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 233,754.00 |
| Sep 30, 2025 | 9,019.00 |
| Jun 30, 2025 | 11,915.00 |
| Mar 31, 2025 | 9,136.00 |
| Dec 31, 2024 | -69,271.00 |
| Sep 30, 2024 | -97,474.00 |
| Jun 30, 2024 | 870,200.00 |
| Mar 31, 2024 | -63,405.00 |
| Dec 31, 2023 | 105,997.00 |
| Sep 30, 2023 | -332,062.00 |